Efficacy of Entecavir-Tenofovir Combination Therapy for Chronic Hepatitis B Patients with Multidrug-Resistant Strains

• DOI: 10.1128/aac.03845-14
• Publication Date: 2014-08-26T06:40:17Z
• Authors: Yun Bin Lee; Jeong-Hoon Lee; Dong Hyeon Lee; Hyeki Cho; Hongkeun Ahn; Won-Mook Choi; Young Youn Cho; Minjong Lee; Jeong-Ju Yoo; Yuri Cho; Eun Ju Cho; Su Jong Yu; Yoon Jun Kim; Jung-Hwan Yoon; Chung Yong Kim; Hyo-Suk Lee
• Keywords: Entecavir; Tenofovir; Combination therapy

ABSTRACT The emergence of multidrug-resistant (MDR) strains hepatitis B virus (HBV) is a major concern. This study aimed to investigate the efficacy and safety combination therapy with entecavir (ETV) plus tenofovir disoproxil fumarate (TDF) against MDR HBV. To adjust for differences in baseline characteristics, inverse probability weighting (IPW) using propensity scores entire cohort weighted Cox proportional hazards models were applied. Ninety-three consecutive patients who treated ETV-TDF >6 months included; at baseline, 45 infected HBV genotypic resistance lamivudine (LAM) ETV (the LAM/ETV-R group), 28 resistant LAM adefovir (ADV) LAM/ADV-R 20 LAM, ETV, ADV LAM/ETV/ADV-R group). median duration rescue was 13.0 (range, 6.7 31.7) months. Seventy-four 93 (79.6%) achieved complete virologic suppression, after 4.5 (95% confidence interval, 3.0 6.0) cumulative suppression month 6 63.6% (55.7%, 75.0%, 65.0% LAM/ETV-R, LAM/ADV-R, groups, respectively). During treatment period, these probabilities not significantly different across profiles before IPW ( P = 0.072 0.510, In multivariate analysis, lower DNA level, but profiles, an independent predictor suppression. Renal dysfunction observed during period. conclusion, efficient safe regardless antiviral drug profiles.